US5792458A
(en)
*
|
1987-10-05 |
1998-08-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Mutant diphtheria toxin conjugates
|
US5352447A
(en)
*
|
1987-10-05 |
1994-10-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
WO1993010819A1
(en)
*
|
1991-11-26 |
1993-06-10 |
Alkermes, Inc. |
Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5268164A
(en)
*
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
US5981194A
(en)
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
DE69328430T2
(de)
*
|
1992-07-27 |
2001-01-25 |
Us Health |
Zielgerichte liposome zur blut-hirne schranke
|
EP0599303A3
(de)
*
|
1992-11-27 |
1998-07-29 |
Takeda Chemical Industries, Ltd. |
Peptide-Konjugate
|
WO1995007092A1
(en)
*
|
1993-09-10 |
1995-03-16 |
The University Of Medicine And Dentistry Of New Jersey |
Blood-brain barrier transporters of neurological agents
|
HUT75469A
(en)
*
|
1994-02-28 |
1997-05-28 |
Medinova Med Consulting Gmbh |
Drug targeting system, method for preparing same and its use
|
US5545553A
(en)
*
|
1994-09-26 |
1996-08-13 |
The Rockefeller University |
Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5817789A
(en)
|
1995-06-06 |
1998-10-06 |
Transkaryotic Therapies, Inc. |
Chimeric proteins for use in transport of a selected substance into cells
|
US6331289B1
(en)
*
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
US6261537B1
(en)
*
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
US20070036722A1
(en)
*
|
1996-10-28 |
2007-02-15 |
Pal Rongved |
Separation processes
|
ATE318618T1
(de)
|
1996-10-28 |
2006-03-15 |
Amersham Health As |
Verbesserungen an oder in verbindung mit diagnotischen/therapeutischen verbindungen
|
IT1291114B1
(it)
|
1997-03-20 |
1998-12-29 |
Angeletti P Ist Richerche Bio |
Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
|
US20040229908A1
(en)
*
|
1999-07-13 |
2004-11-18 |
Jodi Nelson |
Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
|
DE60042215D1
(de)
|
1999-07-13 |
2009-06-25 |
Alpha Res Group Llc |
Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
|
US20020198231A1
(en)
*
|
1999-07-13 |
2002-12-26 |
Jodi Nelson |
Compositions and methods for the treatment of Parkinson's disease
|
WO2001007084A1
(en)
*
|
1999-07-23 |
2001-02-01 |
Regents Of The University Of California |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
|
EP1285272A2
(de)
*
|
2000-02-08 |
2003-02-26 |
University of British Columbia |
Zusammensetzungen und verfahren zum screenen von therapeutischen agenzien
|
US7235397B1
(en)
*
|
2000-04-14 |
2007-06-26 |
Gensys, Inc. |
Methods and compositions for culturing spirochete and treating spirochetal diseases
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
GB0103174D0
(en)
*
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Plc |
Novel method of treatment
|
US20040096880A1
(en)
*
|
2001-08-07 |
2004-05-20 |
Kmiec Eric B. |
Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
|
US20030109476A1
(en)
*
|
2001-08-07 |
2003-06-12 |
Kmiec Eric B. |
Compositions and methods for the prevention and treatment of Huntington's disease
|
US7265084B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7297511B2
(en)
*
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
DK2279753T3
(en)
|
2001-10-10 |
2015-11-23 |
Novo Nordisk As |
The conversion of peptides and glycokonjugering
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7399613B2
(en)
*
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7439043B2
(en)
*
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
US7226903B2
(en)
*
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
PT2279755E
(pt)
|
2001-10-10 |
2014-06-04 |
Ratiopharm Gmbh |
Remodelação e glicoconjugação do factor de crescimento de fibroblastos (fgf)
|
US7265085B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7125843B2
(en)
*
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7157277B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7473680B2
(en)
*
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
MXPA04012496A
(es)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
US20040127409A1
(en)
*
|
2002-11-07 |
2004-07-01 |
Milkhaus Laboratory, Inc. |
Method of treatment of psychological conditions by administration of nerve growth factor
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
JP2006523211A
(ja)
|
2003-03-14 |
2006-10-12 |
ネオス テクノロジーズ インコーポレイテッド |
分岐水溶性ポリマーとその複合物
|
GB0306309D0
(en)
*
|
2003-03-19 |
2003-04-23 |
Glaxo Group Ltd |
Method of treatment
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
EP1615945B1
(de)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
|
US7691603B2
(en)
*
|
2003-04-09 |
2010-04-06 |
Novo Nordisk A/S |
Intracellular formation of peptide conjugates
|
CA2524936A1
(en)
|
2003-05-09 |
2004-12-02 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of human growth hormone glycosylation mutants
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
JP4719686B2
(ja)
*
|
2003-11-24 |
2011-07-06 |
バイオジェネリックス アーゲー |
GlycoPEG化エリスロポエチン
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7956032B2
(en)
*
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20080318850A1
(en)
*
|
2003-12-03 |
2008-12-25 |
Neose Technologies, Inc. |
Glycopegylated Factor Ix
|
EP1765853B1
(de)
|
2004-01-08 |
2015-10-28 |
ratiopharm GmbH |
O-Glykosylierung von G-CSF Peptiden
|
US20050202075A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Pardridge William M. |
Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
|
AU2005243427B2
(en)
*
|
2004-05-04 |
2010-07-22 |
Novo Nordisk Health Care Ag |
O-linked glycoforms of polypeptides and method to manufacture them
|
WO2006009825A1
(en)
|
2004-06-17 |
2006-01-26 |
Virun, Inc. |
Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
US20080108557A1
(en)
*
|
2004-09-29 |
2008-05-08 |
Novo Nordisk Healthcare A/G |
Modified Proteins
|
EP3061461A1
(de)
|
2004-10-29 |
2016-08-31 |
ratiopharm GmbH |
Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
|
WO2006074467A2
(en)
|
2005-01-10 |
2006-07-13 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
US20060246544A1
(en)
*
|
2005-03-30 |
2006-11-02 |
Neose Technologies,Inc. |
Manufacturing process for the production of peptides grown in insect cell lines
|
EP1871795A4
(de)
*
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
|
WO2006127910A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
EP1891231A4
(de)
*
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
Glykopegylierter faktor ix
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
CA2619969A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Neose Technologies, Inc. |
Glycopegylated factor vii and factor viia
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
US8142781B2
(en)
*
|
2005-10-07 |
2012-03-27 |
Armagen Technologies, Inc. |
Fusion proteins for blood-brain barrier delivery
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
WO2007127439A2
(en)
|
2006-04-28 |
2007-11-08 |
Children's Hospital Medical Center |
Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
|
WO2007131034A1
(en)
*
|
2006-05-03 |
2007-11-15 |
The Regents Of The University Of Michigan |
Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
WO2008022349A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
EP2054521A4
(de)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Verfahren zur reinigung von polypeptid-konjugate
|
WO2008073620A2
(en)
*
|
2006-11-02 |
2008-06-19 |
Neose Technologies, Inc. |
Manufacturing process for the production of polypeptides expressed in insect cell-lines
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
WO2008137066A1
(en)
*
|
2007-05-02 |
2008-11-13 |
The Board Of Regents Of The University Of Oklahoma |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
US20090053167A1
(en)
*
|
2007-05-14 |
2009-02-26 |
Neose Technologies, Inc. |
C-, S- and N-glycosylation of peptides
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
US8974791B2
(en)
|
2007-07-27 |
2015-03-10 |
Armagen Technologies, Inc. |
Methods and compositions for increasing α-L-iduronidase activity in the CNS
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
JP2012515790A
(ja)
*
|
2009-01-23 |
2012-07-12 |
サーモディクス ファーマシューティカルズ, インコーポレイテッド |
微粒子製造のための連続二重エマルジョン工程
|
WO2010108048A2
(en)
|
2009-03-18 |
2010-09-23 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
EP2485761B1
(de)
|
2009-10-09 |
2019-02-27 |
Armagen, Inc. |
Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns
|
US8901129B2
(en)
|
2009-12-11 |
2014-12-02 |
Genecode As |
Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
|
UA117801C2
(uk)
|
2010-11-30 |
2018-10-10 |
Дженентек, Інк. |
Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру
|
EP3711778A1
(de)
|
2011-12-02 |
2020-09-23 |
Armagen, Inc. |
Verfahren und zusammensetzungen für erhöhte sulfatase-a-aktivität im zns
|
US10494440B2
(en)
*
|
2012-05-11 |
2019-12-03 |
Vaccinex, Inc. |
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
|
EP3450557A1
(de)
|
2013-12-25 |
2019-03-06 |
JCR Pharmaceuticals Co., Ltd. |
Durch die blut-hirn-schranke passierender, neuartiger anti-transferrin-rezeptorantikörper
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
EP4074730A1
(de)
|
2015-06-24 |
2022-10-19 |
F. Hoffmann-La Roche AG |
Anti-transferrin-rezeptor-antikörper mit angepasster affinität
|
JP6914193B2
(ja)
*
|
2015-06-24 |
2021-08-04 |
Jcrファーマ株式会社 |
Bdnfを含む融合蛋白質
|
EA039366B1
(ru)
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
AU2017385274B2
(en)
|
2016-12-26 |
2024-02-22 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein including BDNF
|
US10759864B2
(en)
|
2016-12-26 |
2020-09-01 |
Jcr Pharmaceuticals Co., Ltd. |
Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
|
PL3583120T3
(pl)
|
2017-02-17 |
2023-01-09 |
Denali Therapeutics Inc. |
Konstruowane polipeptydy wiążące receptory transferyny
|
EP4351726A1
(de)
|
2021-06-11 |
2024-04-17 |
BioArctic AB |
Bispezifisches bindungsmolekül
|